Table 3. Summary of stage and treatment of women with non-high-grade serous epithelial ovarian cancer diagnosed between randomisation and Dec 31, 2014.
| No screening group (clinically diagnosed) | Multimodal screening group | Ultrasound screening group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Screen detected | Clinically diagnosed | Total | p value* | Screen detected | Clinically diagnosed | Total | p value* | |||
| Randomly assigned and eligible women | 101314 | ·· | ·· | 50 625 | ·· | ·· | ·· | 50 623 | ·· | |
| Randomly assigned women who developed non-high-grade serous cancer by intention to screen | 93/101314 (<1%) | 52/50 625 (<1%) | 0·55 | 34/50 623 (<1%) | 0·20 | |||||
| Cancers by screening status | 93 | 27 | 25 | ·· | ·· | 24 | 10 | ·· | ·· | |
| Advanced stage by screening status† | 19/93 (20%) | 4/27 (15%) | 3/25 (12%) | ·· | ·· | 4/24 (17%) | 5/10 (50%) | ·· | ·· | |
| Advanced stage by Intention to screen† | 19/93 (20%) | ·· | ·· | 7/52 (13%) | 0·29 | ·· | ·· | 9/34 (26%) | 0·47 | |
| Primary surgery by screening status | 88/93 (95%) | 27/27 (100%) | 24/25 (96%) | ·· | ·· | 23/24 (96%) | 8/10 (80%) | ·· | ·· | |
| Primary surgery by intention to screen | 88/93 (95%) | ·· | ·· | 51/52 (98%) | 0·37 | ·· | ·· | 31/34 (91%) | 0·41 | |
| Zero residual after surgery by screening status | 80/93 (86%) | 24/27 (89%) | 21/25 (84%) | ·· | ·· | 20/24 (83%) | 7/10 (70%) | ·· | ·· | |
| Zero residual after surgery on intention to screen | 80/93 (86%) | ·· | ·· | 45/52 (87%) | 0·87 | ·· | ·· | 27/34 (79%) | 0·34 | |
| Surgery and chemotherapy by screening status | 66/93 (71%) | 17/27 (63%) | 15/25 (60%) | ·· | ·· | 18/24 (75%) | 4/10 (40%) | ·· | ·· | |
| Surgery and chemotherapy by intention to screen | 66/93 (71%) | ·· | ·· | 32/52 (62%) | 0·27 | ·· | ·· | 22/34 (65%) | 0·52 | |
| Combination chemotherapy by screening status* | 34/93 (37%) | 7/27 (26%) | 9/25 (36%) | ·· | ·· | 10/24 (42%) | 1/10 (10%) | ·· | ·· | |
| Combination chemotherapy by intention to screen* | 34/93 (37%) | ·· | ·· | 16/52 (31%) | 0·48 | ·· | ·· | 11/34 (32%) | 0·66 | |
| Subgroup analyses | ||||||||||
| Treatment in women with stage IA and IB | 24 | 9 | 10 | 7 | 4 | ·· | ||||
| Surgery and chemotherapy by screening status | 8/24 (33%) | 3/9 (33%) | 2/10 (20%) | 2/7 (29%) | 0 | ·· | ||||
| Surgery and chemotherapy by intention to screen | 8/24 (33%) | 5/19 (26%) | 0·62 | ·· | 2/11 (18%) | 0·37 | ||||
| Combination chemotherapy by screening status‡ | 3/24 (13%) | 2/9 (22%) | 1/10 (10%) | 0 | 0 | ·· | ||||
| Combination chemotherapy by intention to screen‡ | 3/24 (13%) | 3/19 (16%) | 0·76 | 0 | 0·22 | |||||
| Treatment in women with stage IC or higher§ | 69 | 18 | 15 | 17 | 6 | ·· | ||||
| Primary surgery by screening status | 64/69 (93%) | 18/18 (100%) | 14/15 (93%) | 16/17 (70%) | 4/6 (67%) | ·· | ||||
| Primary surgery by intention to screen | 64/69 (93%) | 32/33 (97%) | 0·40 | 20/23 (87%) | 0·39 | |||||
| Zero residual after surgery by screening status | 56/69 (81%) | 15/18 (83%) | 11/15 (73%) | 13/17 (57%) | 3/6 (50%) | ·· | ||||
| Zero residual after surgery on intention to screen | 56/69 (81%) | 26/33 (79%) | 0·78 | 16/23 (70%) | 0·24 | |||||
| Surgery and chemotherapy by screening status | 58/69 (84%) | 14/18 (78%) | 13/15 (87%) | 16/17 (70%) | 4/6 (67%) | ·· | ||||
| Surgery and chemotherapy by intention to screen | 58/69 (84%) | 27/33 (82%) | 0·78 | 20/23 (87%) | 0·74 | |||||
| Combination chemotherapy by screening status‡ | 31/69 (45%) | 5/18 (28%) | 8/15 (53%) | 10/17 (59%) | 1/6 (17%) | ·· | ||||
| Combination chemotherapy by intention to screen‡ | 31/69 (45%) | 13/33 (39%) | 0·60 | 11/23 (48%) | 0·81 | |||||
Data are n or n/N (%).
*
All comparisons are intention to screen between the screening group (multimodal or ultrasound) and the no screening group.
†
FIGO 2014 cancer stages III, IV, or unable to stage.
‡
Combination chemotherapy includes trial drugs; majority of patients received platinum and taxol.
§
Stage IC–IV and unable to stage.